Moldova vs Rwanda: Average cost of drugs for extensively drug-resistant tuberculosis
Moldova
1,400 constant 2022 US$
in 2024
Rwanda
1,483 constant 2022 US$
in 2024
Moldova rank
36th
Rwanda rank
35th
Average cost of drugs for extensively drug-resistant tuberculosis over time
- Moldova
- Rwanda
How they compare
Rwanda currently reports 1,483 constant 2022 US$ against 1,400 constant 2022 US$ in Moldova, a difference of 83 constant 2022 US$.
That makes Rwanda's figure about 1.1 times Moldova's.
The two have swapped places 4 times across 8 shared years of data; in 2017 it was Rwanda ahead.
Moldova ranks 36th and Rwanda ranks 35th of 56 countries.
Across the 2 decades both report, Moldova averaged higher in 1 and Rwanda in 1.
Head to head by decade
| Decade | Moldova | Rwanda | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 5,922 constant 2022 US$ | 5,647 constant 2022 US$ | 275 constant 2022 US$ | Moldova |
| 2020s | 2,970 constant 2022 US$ | 3,070 constant 2022 US$ | 100.2 constant 2022 US$ | Rwanda |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of drugs for extensively drug-resistant tuberculosis, Moldova or Rwanda?
- Rwanda, at 1,483 constant 2022 US$ against 1,400 constant 2022 US$ in Moldova as of 2024.
- What is the difference in average cost of drugs for extensively drug-resistant tuberculosis between Moldova and Rwanda?
- 83 constant 2022 US$, with Rwanda ahead.
- How many years of comparable data are there for Moldova and Rwanda?
- 8 years are reported by both, from 2017 to 2024.
- How do Moldova and Rwanda rank globally for average cost of drugs for extensively drug-resistant tuberculosis?
- Moldova ranks 36th and Rwanda ranks 35th of 56 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of drugs for extensively drug-resistant tuberculosis. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting extensively drug-resistant tuberculosis treatment, excluding buffer stock.